search
Back to results

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Primary Purpose

Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
alvespimycin hydrochloride
laboratory biomarker analysis
Sponsored by
National Cancer Institute (NCI)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anaplastic Large Cell Lymphoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Histologically confirmed solid tumor or lymphoma Metastatic or unresectable disease Standard curative or palliative measures do not exist or are no longer effective No known brain metastases Performance status - ECOG 0-2 Performance status - Karnofsky 60-100% More than 12 weeks Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL ALT and AST ≤ 1.5 times upper limit of normal (ULN) Bilirubin ≤ normal Creatinine ≤ 1.25 times ULN Creatinine clearance ≥ 60 mL/min QTc < 450 msec for male patients (470 msec for female patients) LVEF > 40% by MUGA No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row) No myocardial infarction or active ischemic heart disease within the past year No New York Heart Association class III or IV congestive heart failure No poorly controlled angina No uncontrolled dysrhythmia requiring medication No left bundle branch block No history of congenital long QT syndrome No other significant cardiac disease Pulse oximetry at rest or on exercise > 88% No symptomatic pulmonary disease (e.g., chronic obstructive or restrictive pulmonary disease, etc.) or any of the following are allowed: Pulmonary disease requiring medication History of dyspnea, dyspnea on exertion, or paroxysmal nocturnal dyspnea Patients meeting the Medicare criteria for home oxygen or are on oxygen Not pregnant or nursing Negative pregnancy test Fertile patients must use effective double barrier contraception 1 week before, during, and for at least 2 weeks after study participation No uncontrolled illness No active or ongoing infection No history of allergic reaction attributed to compounds of similar chemical or biological composition to 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) No psychiatric illness or social situation that would preclude study compliance No concurrent routine colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered Concurrent hormonal therapy allowed At least 4 weeks since prior radiotherapy and recovered No prior radiation that included the heart in the field (e.g., mantle) No concurrent combination antiretroviral therapy for HIV-positive patients No other concurrent anticancer agents or therapies No concurrent medication that would prolong the QTc interval No other concurrent investigational agents

Sites / Locations

  • University of Pittsburgh

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment (alvespimycin hydrochloride)

Arm Description

Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Outcomes

Primary Outcome Measures

Maximum tolerated dose of alvespimycin hydrochloride
Toxicity graded using the NCI CTCAE version 3.0
Recommended phase II dose (RP2D) of alvespimycin hydrochloride for future studies determined by toxicity assessments
Pharmacokinetics of alvespimycin hydrochloride in blood, urine, and tumor tissue
Analyzed by both non-compartmental and compartmental methods.

Secondary Outcome Measures

Tumor response assessed by tumor measurements

Full Information

First Posted
August 4, 2004
Last Updated
January 24, 2013
Sponsor
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00089271
Brief Title
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Official Title
A Phase I Study Of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin, (17-DMAG) (NSC 707545) In Patients With Advanced Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
July 2004 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary
This phase I trial is studying the side effects and best dose of 17-DMAG in treating patients with metastatic or unresectable solid tumors or lymphomas. Drugs used in chemotherapy, such as 17-DMAG, work in different ways to stop cancer cells from dividing so they stop growing or die
Detailed Description
PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in patients with metastatic or unresectable solid tumors or lymphomas. II. Determine the safety and toxicity of this drug in these patients. III. Determine the pharmacokinetics and pharmacodynamics of this drug in these patients. IV. Determine the recommended phase II dose of this drug for future studies. SECONDARY OBJECTIVES: I. Determine tumor response in patients treated with this drug. OUTLINE: This is a dose-escalation, multicenter study. Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 1-2 patients receive accelerated escalating doses of 17-DMAG until at least 1 of 2 patients experience dose-limiting toxicity (DLT). Cohorts are then expanded to 3-6 patients who receive escalating doses (in a standard manner) of 17-DMAG until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Patients are followed at 4 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment (alvespimycin hydrochloride)
Arm Type
Experimental
Arm Description
Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Intervention Type
Drug
Intervention Name(s)
alvespimycin hydrochloride
Other Intervention Name(s)
17-DMAG HCL, KOS-1022
Intervention Description
Given IV
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Description
Correlative studies
Primary Outcome Measure Information:
Title
Maximum tolerated dose of alvespimycin hydrochloride
Time Frame
21 days
Title
Toxicity graded using the NCI CTCAE version 3.0
Time Frame
Up to 4 weeks
Title
Recommended phase II dose (RP2D) of alvespimycin hydrochloride for future studies determined by toxicity assessments
Time Frame
21 days
Title
Pharmacokinetics of alvespimycin hydrochloride in blood, urine, and tumor tissue
Description
Analyzed by both non-compartmental and compartmental methods.
Time Frame
21 days
Secondary Outcome Measure Information:
Title
Tumor response assessed by tumor measurements
Time Frame
Up to 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed solid tumor or lymphoma Metastatic or unresectable disease Standard curative or palliative measures do not exist or are no longer effective No known brain metastases Performance status - ECOG 0-2 Performance status - Karnofsky 60-100% More than 12 weeks Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL ALT and AST ≤ 1.5 times upper limit of normal (ULN) Bilirubin ≤ normal Creatinine ≤ 1.25 times ULN Creatinine clearance ≥ 60 mL/min QTc < 450 msec for male patients (470 msec for female patients) LVEF > 40% by MUGA No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row) No myocardial infarction or active ischemic heart disease within the past year No New York Heart Association class III or IV congestive heart failure No poorly controlled angina No uncontrolled dysrhythmia requiring medication No left bundle branch block No history of congenital long QT syndrome No other significant cardiac disease Pulse oximetry at rest or on exercise > 88% No symptomatic pulmonary disease (e.g., chronic obstructive or restrictive pulmonary disease, etc.) or any of the following are allowed: Pulmonary disease requiring medication History of dyspnea, dyspnea on exertion, or paroxysmal nocturnal dyspnea Patients meeting the Medicare criteria for home oxygen or are on oxygen Not pregnant or nursing Negative pregnancy test Fertile patients must use effective double barrier contraception 1 week before, during, and for at least 2 weeks after study participation No uncontrolled illness No active or ongoing infection No history of allergic reaction attributed to compounds of similar chemical or biological composition to 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) No psychiatric illness or social situation that would preclude study compliance No concurrent routine colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered Concurrent hormonal therapy allowed At least 4 weeks since prior radiotherapy and recovered No prior radiation that included the heart in the field (e.g., mantle) No concurrent combination antiretroviral therapy for HIV-positive patients No other concurrent anticancer agents or therapies No concurrent medication that would prolong the QTc interval No other concurrent investigational agents
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chandra Belani
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States

12. IPD Sharing Statement

Learn more about this trial

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

We'll reach out to this number within 24 hrs